Review
Open access
Aug 2026
Dasatinib as a Network-modulating Tyrosine Kinase Inhibitor in Philadelphia Chromosome-positive Leukemias: Integration of BCR-ABL1, SRC, and MAPK Signaling
This review combines many forms of evidence, including mechanistic, phosphoproteomic, immunologic and clinical evidence, to show that dasatinib acts as a network-modulating tyrosine kinase inhibitor rather than only as an ABL1-directed agent.
S. Vanitha, R. Kothai, B. Arul
· Journal of Applied Pharmaceu... · 0 citations